Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EQUIFAX INCEFX · Entity 3235 | CVP and CMO | February 22, 2019 | February 27, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EQUIFAX INC
Report date February 22, 2019 · Filed February 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,566 |
Reported balance
After 2019-02-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-02-22 · Grant · Acquired 1,580 · Balance 8,566 F1: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/22/2022. F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. |
| Stock Option/Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $149.53 · Expires 2025-02-22 | Direct | 8,738 |
Reported balance
After 2019-02-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-22 · Grant · Acquired 8,738 · Balance 8,738 F3: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022. |
| Stock Option/Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $138.45 · Expires 2025-02-22 | Direct | 7,244 |
Reported balance
After 2019-02-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-22 · Grant · Acquired 7,244 · Balance 7,244 F3: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022. |
| Stock Option/Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $127.37 · Expires 2025-02-22 | Direct | 5,995 |
Reported balance
After 2019-02-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-22 · Grant · Acquired 5,995 · Balance 5,995 F3: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 936 |
Reported balance
Holding disclosure · report date 2019-02-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 936 |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/22/2022.
F2: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date.
F3: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2019 Filed Feb 27, 2019 01:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 5,995 | $0.00 Strike: $127.37 | $0.00 |
DisclosureSEC source: 0001225208-19-003795 · doc4.xml · derivative · entry 5 Wilbanks Laura Louise · CIK 0001713229 · CVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,995 Underlying: Common Stock · 5,995 shares Expires 2025-02-22 F3 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 01:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 7,244 | $0.00 Strike: $138.45 | $0.00 |
DisclosureSEC source: 0001225208-19-003795 · doc4.xml · derivative · entry 4 Wilbanks Laura Louise · CIK 0001713229 · CVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,244 Underlying: Common Stock · 7,244 shares Expires 2025-02-22 F3 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 01:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 8,738 | $0.00 Strike: $149.53 | $0.00 |
DisclosureSEC source: 0001225208-19-003795 · doc4.xml · derivative · entry 3 Wilbanks Laura Louise · CIK 0001713229 · CVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,738 Underlying: Common Stock · 8,738 shares Expires 2025-02-22 F3 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests 100% on 2/22/2022. Read SEC document |
| February 22, 2019 Filed Feb 27, 2019 01:30 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 1,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003795 · doc4.xml · nonDerivative · entry 1 Wilbanks Laura Louise · CIK 0001713229 · CVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,566 F1 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 2/22/2022. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| September 30, 2018 Filed Oct 2, 2018 20:17 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 642 | $130.79 | $83,967.18 |
DisclosureSEC source: 0001225208-18-014084 · doc4.xml · nonDerivative · entry 1 Wilbanks Laura Louise · CIK 0001713229 · CVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,978 F1 · acquired: Reflects withholding of shares to satisfy tax withholding obligation upon vesting of prior equity awards. F2 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:20 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Option/Right to Buy · Derivative | 5,770 | $0.00 Strike: $121.35 | $0.00 |
DisclosureSEC source: 0001225208-18-005681 · doc4.xml · derivative · entry 4 Wilbanks Laura Louise · CIK 0001713229 · CVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,770 Underlying: Common Stock · 5,770 shares Expires 2028-03-05 F4 · derivative.exercise_date: Annual equity grant pursuant to the Company's long-term incentive plan. The option vests in three equal annual increments beginning 3/5/2019. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:20 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 1,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-005681 · doc4.xml · nonDerivative · entry 2 Wilbanks Laura Louise · CIK 0001713229 · CVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,602 F2 · security: Annual equity grant pursuant to the Company's long-term incentive plan. The award of restricted stock units vests 100% on 3/5/2021. F3 · balance_after: Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. Read SEC document |
| October 01, 2017 Filed Mar 7, 2018 22:20 UTC | EQUIFAX INC EFX · Entity 3235 | Tax withholdingCommon Stock | 568 | $107.81 | $61,236.08 |
DisclosureSEC source: 0001225208-18-005681 · doc4.xml · nonDerivative · entry 1 Wilbanks Laura Louise · CIK 0001713229 · CVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,157 F1 · acquired: Reflects withholding of shares to satisfy tax withholding obligation upon vesting of prior equity awards. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:21 UTC | EQUIFAX INC EFX · Entity 3235 | GrantStock Options/Right to Buy · Derivative | 2,051 | $0.00 Strike: $146.26 | $0.00 |
DisclosureSEC source: 0000899243-17-019690 · doc4.xml · derivative · entry 3 Wilbanks Laura Louise · CIK 0001713229 · CVP & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,051 Underlying: Common Stock · 2,051 shares Expires 2027-08-01 F2 · derivative.exercise_date: The option vests in three equal annual increments beginning 8/1/2018. Read SEC document |
| August 01, 2017 Filed Aug 3, 2017 20:21 UTC | EQUIFAX INC EFX · Entity 3235 | GrantCommon Stock | 513 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-019690 · doc4.xml · nonDerivative · entry 1 Wilbanks Laura Louise · CIK 0001713229 · CVP & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,725 F1 · security: Award of restricted stock units. The stock vests 100% on 8/1/2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.